Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Trial of new therapy for pancreatic cancer

Patients in Liverpool are to trial a new therapy for pancreatic cancer - a disease which sees most sufferers die within a year of diagnosis.

15 Mar 2007

Squalenoyl nanomedicines as potential therapeutics

Nucleoside analogs such as cytarabine and gemcitabine are powerful anticancer agents, but a simple chemical modification that causes them to assemble into stable nanoparticles could make them even more valuable in the treatment of a wide variety of cancers.

23 Oct 2006

Study: Collecting duct carcinoma

Collecting duct carcinoma is a rare and highly aggressive variant of renal cell carcinoma that frequently presents with advanced disease, has few effective treatment options, and is associated with a poor prognosis.

17 Aug 2006

Combining chemotherapy with radiation therapy after the surgical removal of cancer in the pancreas improves survival

Patients with pancreatic cancer, a historically difficult-to-treat cancer with poor survival rates, may benefit from treatments studied in an international, multi-center research trial.

26 Jul 2006

FDA approval for Gemzar for ovarian cancer

Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Gemzar (gemcitabine HCl) for use in the treatment of women living with recurrent ovarian cancer.

18 Jul 2006

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Nicotine and chemotherapy not a good mix

Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.

3 Apr 2006

Capecitabine and Gemcitabine help battle pancreatic cancer

The prognosis of pancreatic cancer is poor but new therapies such as gemcitabine have contributed to improving the outcome for patients. Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients.

3 Nov 2005

Lung cancer drug approved for treating pancreatic cancer

Genentech and OSI Pharmaceuticals have announced that U.S. regulators have approved their lung cancer drug Tarceva for the treatment of pancreatic cancer.

3 Nov 2005

New chemo combo means longer life for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat, and has an overall one-year survival rate of only 13%.

3 Nov 2005

First advance in pancreatic cancer treatment in a decade offers new hope

The first advance in pancreatic cancer treatment in a decade has been achieved by researchers in a Canadian-led study, and at last gives some encouragement to scientists and invigorates a field that has experienced more than its share of disheartening failures.

15 May 2005

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.

9 May 2005

Discovery of key molecule that controls the growth, spread and survival of pancreatic cancer cells

Pancreatic cancer kills 30,000 Americans every year. Not only is there no cure, but there are no effective treatments. That may change if a new finding by Mayo Clinic researchers continues to show promise.

15 Mar 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

FDA approves Tarceva (erlotinib)

OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

20 Nov 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

Bladder-sparing treatment shows promise against cancer

For patients with invasive bladder cancer, treatment has typically meant an operation to remove the bladder and nearby organs. This requires up to a week in the hospital and leaves patients with a reconstructed bladder or urostomy bag.

21 Jul 2004

Benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience

Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience, especially in advanced stages of the disease.

15 Jun 2004